Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02773992
Other study ID # 201501014
Secondary ID
Status Recruiting
Phase N/A
First received May 3, 2016
Last updated May 13, 2016
Start date August 2015
Est. completion date August 2020

Study information

Verified date May 2016
Source Henan Provincial Hospital
Contact zhang xiaoju
Phone 15837101166
Email 15837101166@163.com
Is FDA regulated No
Health authority China: Health and Family Planning Commission of Henan Province
Study type Observational

Clinical Trial Summary

Medical The Internet of Things (IoT), a recent breakthrough in communication technology, could be helpful in improving health care delivery and saving medical costs, but regarding pulmonary nodule management it is still at the basic understanding. Investigators adopt "Internet of things medical three plus two type pulmonary nodule diagnosis" which chun-xue Bai put forward, used a developed a mobile phone-based IoT (mIoT) platform and initiated a randomized, multicenter, controlled trial to value clinical effectivity of "Internet of things medical three plus two type pulmonary nodule diagnosis" in the management of pulmonary nodules. In this study, at least 600 patients with pulmonary nodules (no typical symptoms, often single, clear boundary, increased density, soft tissue shadow surrounded by lung parenchyma with diameter ≤3 cm) will be randomly allocated to the control group, which receives routine follow-up, or the intervention group, which receives "Internet of things medical three plus two type pulmonary nodule diagnosis" management. Endpoints of the study include: (1) The positive diagnosis rate of lung cancer in I stage; (2) 5 year disease-free survival rate and overall survival rate; (3) direct medical costs per year. Results from this study should provide direct evidence for the suitability of "Internet of things medical three plus two type pulmonary nodule diagnosis" in pulmonary nodules patients management.


Description:

The flow chart of the study design is shown in Figure 1.After enrollment, participants are randomly assigned into two groups: the IoT group and the routine management group. For both groups, participants are gathered basic information (age, sex, smoking and smoking status, family history of cancer, family history of lung disease,Other malignant tumor history, drug using history and its effect during a fever). For the IoT group, "three plus two type pulmonary nodule diagnosis" which professor Bai put forward is carried out on participants: three basic steps: ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected participants: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage participants scientifically in accordance with the follow-up management tables through the Internet of things platform (Researchkit). The routine management group are completely managed by investigators' personal experience.

Follow-up Researchkit APP based on the android phone system and IOS system is installed in the participant's cellphone for free and all participant are trained to use the software. They are allowed to practice until accurate data submission and collection are ascertained. At the same time, an APP instruction is also provided, with one engineer ready for consultation in case of any technical problems. The following measures are carried out via the Internet platform: ① collect the basic information of the subjects, suggest the date of follow-up according to the the subjects' nodule situation; ② health education is pushed to the subjects' mobile terminal to help them carry out self health management; ③ subjects are asked to report their physical conditions once a month via Researchkit APP; ④ communication with medical staff during work hours is available remotely through the mobile device.

Participant are allowed to make unscheduled clinic visits and emergency visits as necessary. The study period is 5 years. The outcomes will be recorded and the superiority of "iot three plus two diagnosis method" in the management of pulmonary nodules will be evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date August 2020
Est. primary completion date August 2020
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Subjects must meet the following criteria:

Inclusion Criteria:

1. Over 18 years old;

2. Single or multiple round solitary pulmonary nodules surrounded by lung parenchyma without associated atelectasis, diameter < 3 cm of small pulmonary nodules;

3. Patients should be capable of reading and writing Chinese, without impaired verbal communication;

4. Patients should be capable of using intellectual equipment.

Exclusion criteria:

1. Chest CT present lung mass, large seepage or atelectasis;

2. Other active chronic respiratory system diseases needing be diagnosed , intervention and treatment;

3. Severe or uncontrolled complications of other systems;

4. Complicated with pleural effusion;

5. Patients with cognitive impairment or mental abnormalities being unable to complete the questionnaire.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Behavioral:
The IoT
For the IoT group, "three plus two type pulmonary nodule diagnosis": ? gather information: smoking history, tumor personal and family history, copd history, etc.; ? noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ? information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ? Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ? Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform.

Locations

Country Name City State
China XZhang Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Henan Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The positive diagnosis rate of lung cancer in I stage 5 years Yes
See also
  Status Clinical Trial Phase
Terminated NCT05066776 - Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules
Completed NCT01958931 - Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer N/A
Recruiting NCT03528733 - Feasibility of Multi-Energy Digital Radiography Detector for Lung Lesions Detection N/A
Recruiting NCT02693496 - Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research
Completed NCT01566682 - A Multi-Center Trial of the ProLung Test™
Terminated NCT02983903 - Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions N/A
Terminated NCT02050724 - ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT Phase 2
Not yet recruiting NCT04615156 - 18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography Phase 3
Recruiting NCT02726633 - Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer N/A
Active, not recruiting NCT02623712 - The Watch the Spot Trial N/A
Recruiting NCT03568799 - 4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules N/A
Not yet recruiting NCT02817048 - Tubeless VATS for Peripheral Lung Nodule N/A
Recruiting NCT01149187 - Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules N/A
Completed NCT00925210 - Bronchoscopic Approach to the Peripheral Lung Nodule - An Alternative Approach Phase 2
Completed NCT02448225 - 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules Phase 2
Recruiting NCT05171491 - LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules
Terminated NCT04140474 - Evaluation of the Archimedes ™ System for Transparenchymatous Access to Pulmonary Nodules. N/A
Withdrawn NCT05804435 - iNod™ Ultrasound-Guided Needle Biopsy System Study N/A
Not yet recruiting NCT02653859 - Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules N/A
Completed NCT02832284 - iNod System Human Feasibility Assessment N/A